基于个体出血风险的重复时间-事件模型用于血友病A患者的个体化治疗
该研究利用264例重型血友病A患者在三项临床试验中的数据,改进重复时间-事件模型,将患者分为低、中、高出血频率队列,预测特定类型出血的风险而非汇总出血信息。模型预测准确性较高,超过70%的预测值与真实观察出血率相差在1次出血以内,且无需测量新型生物标志物。作者认为该方法可能为血友病A患者提供新的治疗范式。
要点
- 重复时间-事件模型可结合历史年出血率和药代动力学量化个体出血风险。
- 模型将患者分为低、中、高出血频率队列,预测特定类型出血风险。
- 超过70%的预测值与真实观察出血率相差在1次出血以内。
核心结论
- 作者认为所提出的方法可能为血友病A患者提供一种令人兴奋的新治疗范式。
研究设计与样本
- 研究使用264例重型血友病A患者在三项临床试验随访期间的数据,改进现有的重复时间-事件模型。
主要发现
- 模型将患者分为低出血频率、中出血频率或高出血频率队列,以减少患者间变异。
- 模型预测特定类型出血的风险,而非汇总的出血信息。
- 模型准确性较高,超过70%的预测值与真实观察出血率相差在1次出血以内。
关键数值与推荐
- 模型预测准确性:超过70%的预测值与真实观察出血率相差在1次出血以内。
临床怎么用
- 该方法无需测量新型或非常规生物标志物,便于在常规临床实践中采用。
- 所提出的模型可用于比较治疗,不仅基于特定因子水平的达标和因子浓缩物消耗量,还可基于预测的出血结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacokinetic-guided dosing of factor (F)VIII concentrates is widely recommended to personalize the treatment of patients with hemophilia A. However, it is well known that commonly applied target FVIII plasma levels do not necessarily improve bleeding outcomes in all individuals. It is therefore desirable to adapt treatment based on individual bleeding risk rather than only factor levels. Unfortunately, there is currently no reliable clinical marker that reliably differentiates between patients with low or high-bleeding risk. OBJECTIVES: We explore the possibility of using repeated time-to-event models to quantify individual bleeding risk by combining (historical) information on annual bleeding rates and pharmacokinetics, without requiring the measurement of novel clinical markers. METHODS: We improved upon existing repeated time-to-event models using data from 264 patients with severe hemophilia A followed during 3 clinical trials. The model classified patients into low-bleeding, medium-bleeding, or high-bleeding frequency cohorts to reduce between-patient variability and predicted bleeding risk for specific categories of bleeds rather than pooled bleeding information. RESULTS: The resulting model has high accuracy, with >70% of predictions being within 1 bleed of the true observed bleeding rate. We demonstrate how the proposed model can be used to compare treatment based on not only the achievement of specific factor levels and factor concentrate consumption but also on projected bleeding outcomes. Importantly, this approach does not require the measurement of novel or unconventional biomarkers, facilitating its adoption in routine clinical practice. CONCLUSION: The proposed method may present an exciting new treatment paradigm for patients with hemophilia A.
引用
- Janssen A, Bennis FC, Cnossen MH, et al. A repeated time-to-event model for personalized treatment of patients with hemophilia A based on individual bleeding risk. J Thromb Haemost. 2025. PMID: 40447105. doi:10.1016/j.jtha.2025.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。